Artemisia iwayomogiExtract Attenuates High-Fat Diet-Induced Obesity by Decreasing the Expression of Genes Associated with Adipogenesis in Mice

Abstract

The objective of the present study was to determine whether Artemisia iwayomogi (AI) extract reduces visceral fat accumulation and obesity-related biomarkers in mice fed a high-fat diet (HFD), and if so, whether these effects are exerted by modulation of the expression of genes associated with adipogenesis and inflammation. AI extract supplementation for 11 weeks significantly prevented HFD-induced increments in body weight, visceral adiposity, adipocyte hypertrophy, and plasma levels of lipids and leptin. Additionally, AI extract supplementation resulted in downregulation of adipogenic transcription factors (PPARγ2 and C/EBPα) and their target genes (CD36, aP2, and FAS) in epididymal adipose tissue compared to the HFD alone. The AI extract effectively reversed the HFD-induced elevations in plasma glucose and insulin levels and the homeostasis model assessment of insulin resistance index. Furthermore, the extract significantly decreased gene expression of proinflammatory cytokines (TNFα, MCP1, IL-6, IFNα, and INFβ) in epididymal adipose tissue and reduced plasma levels of TNFα and MCP1 as compared to HFD alone. In conclusion, these results suggest that AI extract may prevent HFD-induced obesity and metabolic disorders, probably by downregulating the expression of genes related to adipogenesis and inflammation in visceral adipose tissue.

Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice

“…Obesity is associated with type II diabetes, hypertension and coronary heart disease [2,22,23]. Sulforaphane is involved in the inhibition of adipogenesis and can reduce the risk of cardiovascular disease [17][18][19].…”

Artemisia Iwayomogi Extract Attenuates High-Fat Diet-Induced Hypertriglyceridemia in Mice: Potential Involvement of the Adiponectin-AMPK Pathway and Very Low Density Lipoprotein Assembly in the Liver

“…A hepatoprotective effect of A. iwayomogi extract was reported in rodent models with different types of liver diseases, such as alcoholic fatty liver [ 9 ], carbon tetrachloride-induced chronic hepatic fibrosis [ 10 , 11 ], and cholestatic liver fibrosis [ 12 ]. We previously reported that A. iwayomogi extract (0.5% w / w diet) reduced visceral fat accumulation and obesity-related biomarkers in mice fed a HFD by modulating the expression of genes associated with adipogenesis and inflammation in adipose tissues [ 13 ]. Concurrently in this extract-fed mice, we also observed a decrease in plasma TG levels, however the underlying mechanism responsible was not elucidated.…”

Artemisiae Iwayomogii Herba Inhibits Growth, Motility, and the PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma Cells

“…The aerial parts of AI have been used in traditional medicine to treat various infectious diseases including hepatitis, cholecystitis, carbuncles, and jaundice [9,10]. In particular, AI extracts have shown hepatoprotective effect in animal liver disease models including fatty liver and liver fibrosis [11,12]. Furthermore, a previous study reported that the essential oil isolated from AI induces epidermoid carcinoma cell apoptosis [13].…”